This Article Full Text Full Text (PDF) Supplemental Data Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Google Scholar Articles by Elinav, E. Articles by Gertler, A. PubMed PubMed Citation Articles by Elinav, E. Articles by Gertler, A.

Pegylated Leptin Antagonist Is a Potent Orexigenic Agent: Preparation and Mechanism of Activity

Institute for Gastroenterology and Liver Disease (E.E., M.K., M.A., Z.H.), Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel; The Robert H. Smith Faculty of Agriculture, Food, and the Environment (L.N.-S., M.Y., A.G., G.S., S.R.), The Hebrew University, Rehovot 76100, Israel; and Geriatrics Research Education and Clinical Center (T.O.P., J.L.L., W.A.B.), Veterans Affairs Medical Center-St. Louis, and Division of Geriatrics (T.O.P., J.L.L., W.A.B.), Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri 63106

Address all correspondence and requests for reprints to: Professor Arieh Gertler, Institute of Biochemistry, Food Science, and Nutrition, The Robert H. Smith Faculty of Agriculture, Food, and the Environment, The Hebrew University of Jerusalem, P.O. Box 12, Rehovot 76100, Israel. E-mail: gertler{at}agri.huji.ac.il.

Leptin, a pleiotropic adipokine, is a central regulator of appetite and weight and a key immunomodulatory protein. Although inborn leptin deficiency causes weight gain, it is unclear whether induced leptin deficiency in adult wild-type animals would be orexigenic. Previous work with a potent competitive leptin antagonist did not induce a true metabolic state of leptin deficiency in mice because of a short circulating half-life. In this study, we increased the half-life of the leptin antagonist by pegylation, which resulted in significantly increased bioavailability and retaining of antagonistic activity. Mice administered the pegylated antagonist showed a rapid and dramatic increase in food intake with weight gain. Resulting fat was confined to the mesenteric region with no accumulation in the liver. Serum cholesterol, triglyceride, and hepatic aminotransferases remained unaffected. Weight changes were reversible on cessation of leptin antagonist treatment. The mechanism of severe central leptin deficiency was found to be primarily caused by blockade of transport of circulating leptin across the blood-brain barrier with antagonisms at the arcuate nucleus playing a more minor role. Altogether we introduce a novel compound that induces central and peripheral leptin deficiency. This compound should be useful in exploring the involvement of leptin in metabolic and immune processes and could serve as a therapeutic for the treatment of cachexia.